Every 10-Q that Phibro Animal (PAHC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PAHC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PAHC filings page.
Phibro Animal Health delivered higher Q3 2026 results, with net sales of $383.5 million, up 10% from $347.8 million, and net income of $24.0 million versus $20.9 million. Diluted EPS rose to $0.59 from $0.51.
For the nine months, net sales climbed to $1.12 billion, up 22%, while net income more than doubled to $78.0 million, driven largely by the October 2024 Zoetis portfolio acquisition and strong Animal Health growth. Animal Health revenue reached $864.7 million, up 29%, led by medicated feed additives.
Leverage remains meaningful, with term loans of about $625.9 million and revolver borrowings of $115.0 million, pushing interest expense, net, to $34.2 million for the nine months. The company highlights geopolitical exposure in Israel and regulatory risks around carbadox in the U.S. and antimicrobial growth promoters in Brazil.
Phibro Animal Health Corporation reported sharply stronger results. For the quarter ended December 31, 2025, net sales reached $373.9 million, up 21% from $309.3 million. Net income rose to $27.5 million from $3.2 million, with basic earnings per share increasing to $0.68 from $0.08.
Growth was led by the Animal Health segment, helped by the October 2024 acquisition of Zoetis’s medicated feed additive and water-soluble products portfolio. This portfolio contributed $94.1 million of quarterly revenue and $174.6 million over six months. Six‑month net sales grew 30% to $737.8 million, while net income climbed to $54.0 million from $10.2 million.
Phibro Animal Health (PAHC) reported strong quarterly growth with net sales of $363.9 million for the three months ended September 30, 2025, up 40% year over year. Operating income rose to $51.3 million from $17.7 million, and net income increased to $26.5 million, or $0.65 per diluted share, versus $0.17 a year ago. Gross profit reached $119.8 million.
Animal Health led results with $283.5 million in sales, including medicated feed additives and other products at $195.2 million, nutritional specialties at $48.2 million, and vaccines at $40.1 million. The October 2024 acquisition of select Zoetis products contributed $80.5 million to the quarter’s revenue. By region, sales were $202.3 million in the U.S., $87.2 million in Latin America and Canada, $44.9 million in EMEA, and $29.4 million in Asia Pacific.
Balance sheet and cash flows: cash and cash equivalents were $72.8 million, inventories were $471.8 million, and total assets were $1.39 billion. Long‑term debt was $609.5 million, with $115.0 million drawn on the revolver and $192.1 million remaining available for borrowing and letters of credit. Net cash provided by operating activities was $9.3 million; capital expenditures were $13.8 million. Interest expense, net, was $12.1 million.